"Diclofenac" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
Descriptor ID |
D004008
|
MeSH Number(s) |
D02.241.223.601.210
|
Concept/Terms |
Diclofenac- Diclofenac
- Diclophenac
- Dicrofenac
- Dichlofenal
|
Below are MeSH descriptors whose meaning is more general than "Diclofenac".
Below are MeSH descriptors whose meaning is more specific than "Diclofenac".
This graph shows the total number of publications written about "Diclofenac" by people in this website by year, and whether "Diclofenac" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 1 | 2 |
2003 | 1 | 0 | 1 |
2004 | 3 | 0 | 3 |
2006 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diclofenac" by people in Profiles.
-
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79.
-
Enteric glia promote intestinal mucosal healing via activation of focal adhesion kinase and release of proEGF. Am J Physiol Gastrointest Liver Physiol. 2011 Jun; 300(6):G976-87.
-
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):41-50.
-
Ochronosis in differential diagnosis of patients with chronic backache: a review of the literature. Rheumatol Int. 2007 Nov; 28(1):61-4.
-
Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel. Acta Derm Venereol. 2007; 87(2):188-9.
-
Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Am J Physiol Renal Physiol. 2007 Feb; 292(2):F789-95.
-
Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. Psychopharmacology (Berl). 2005 May; 179(2):356-65.
-
Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004 Jul-Aug; 3(4):401-7.
-
The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. Behav Brain Res. 2004 Feb 04; 149(1):77-85.
-
The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res. 2003 Jul 04; 977(1):70-9.